AlphaCentric Advisors’s Pfizer PFE Stock Holding History

AlphaCentric Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$1.03M	Buy	38,807 +3,807	+11%	+$103K	1.03%	28
2024 Q3	$1.01M	Sell	35,000 -105,000	-75%	-$3.06M	0.75%	45
2024 Q2	$3.92M	Sell	140,000 -35,000	-20%	-$964K	2.88%	4
2024 Q1	$4.86M	Buy	175,000 +95,000	+119%	+$2.64M	2.93%	1
2023 Q4	$2.3M	Buy	+80,000	New	+$2.42M	1.55%	17
2021 Q3	–	Sell	-2,000	Closed	-$78K	–	214
2021 Q2	$78K	Sell	2,000 -2,000	-50%	-$77.8K	0.02%	187
2021 Q1	$145K	Buy	+4,000	New	+$142K	0.05%	118
2020 Q3	–	Sell	-211	Closed	-$7K	–	174
2020 Q2	$7K	Buy	+211	New	+$7.17K	﹤0.01%	140

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AlphaCentric Advisors's PFE Position: Q4 2024 in Review

AlphaCentric Advisors increased its Pfizer (PFE) stake by 11% in Q4 2024, buying an estimated $103K and bringing the position to 38,807 shares worth $1.03M. The position accounts for 1.03% of the portfolio, ranked #28.

AlphaCentric Advisors first reported a position in PFE in Q2 2020 and has held it in 8 quarters since. The position peaked at $4.86M in Q1 2024. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

AlphaCentric Advisors held 38,807 shares of Pfizer worth $1.03M as of Q4 2024.
AlphaCentric Advisors bought 3,807 Pfizer shares in Q4 2024, an estimated $103K.
Pfizer made up 1.03% of AlphaCentric Advisors's portfolio in Q4 2024, its #28 holding.
AlphaCentric Advisors first reported a position in Pfizer in Q2 2020 and has held it in 8 quarters since.
AlphaCentric Advisors's Pfizer position peaked at $4.86M in Q1 2024.
2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.